Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266022 | 0.81 | CA2 (0.61) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL2717291 | 0.80 | ESR1 (0.50) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL4573294 | 0.78 | CA2 (0.62) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL2984207 | 0.78 | CA1 (0.62) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL4371994 | 0.78 | ABAT (0.50) | CA2CA1CA9CA12ABAT | |
| SCHEMBL14536592 | 0.76 | ESR1 (0.46) | CA2CA1CA9CA12ABAT | |
| SCHEMBL1645091 | 0.76 | CA1 (0.60) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL4573291 | 0.76 | CA2 (0.60) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL22266036 | 0.76 | CA2 (0.60) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL3229364 | 0.76 | CA1 (0.60) | CA2CA1CA9CA5ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962834-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Aventis Pharmaceuticals Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067617-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | WO | claimed |
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3074381-B1 | NOVEL DGAT2 INHIBITORS | LILLY CO ELI (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3074381-B1 | NOVEL DGAT2 INHIBITORS | LILLY CO ELI (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3298001-A1 | NOVEL DGAT2 INHIBITORS | Eli Lilly and Company (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187384-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-11-24 | — | — | WO | disclosed |
| EP-3074381-A1 | NOVEL DGAT2 INHIBITORS | Eli Lilly and Company (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015077299-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150148358-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-28 | — | — | US | disclosed |
| WO-2015077299-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150148358-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148358-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-28 | — | — | US | disclosed |
| US-8796489-B2 | Ketobenzofuran derivatives, method for synthesizing same, and intermediates | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-20130012729-A1 | KETOBENZOFURAN DERIVATIVES, METHOD FOR SYNTHESIZING SAME, AND INTERMEDIATES | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| EP-2542544-A1 | KETOBENZOFURAN DERIVATIVES, METHOD FOR SYNTHESISING SAME, AND INTERMEDIATES | SANOFI (FR) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107705-A1 | KETOBENZOFURAN DERIVATIVES, METHOD FOR SYNTHESISING SAME, AND INTERMEDIATES | SANOFI-AVENTIS (FR) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012729-A1 | KETOBENZOFURAN DERIVATIVES, METHOD FOR SYNTHESIZING SAME, AND INTERMEDIATES | NNMT, DHPS, NDUFC1 | CA2 4568/4885CA1 4207/4885CA9 2193/4885 |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | CA2 4773/4885CA1 4849/4885CA9 4583/4885 |
| US-20150148358-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | CA2 4670/4885CA1 4861/4885CA9 4415/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | CA2 4742/4885CA1 4830/4885CA9 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.